research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
Search
for
Sort by
Research
960-990 / 1000+ results
research Novel ALK5 inhibitor TP0427736 reduces TGF-β induced growth inhibition in human outer root sheath cells and elongates anagen phase in mouse hair follicles
TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
research Reduction of Intrafollicular Apoptosis in Chemotherapy-Induced Alopecia by Topical Calcitriol-Analogs
Topical calcitriol-analogs can reduce hair loss caused by chemotherapy.
research Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
Ruxolitinib helped a man regrow his beard after years of hair loss.
research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
research Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab
research Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
research Laminin-511, inducer of hair growth, is down-regulated and its suppressor in hair growth, laminin-332 up-regulated in chemotherapy-induced alopecia
Chemotherapy-induced hair loss is partly due to decreased laminin-511 and increased laminin-332.
research Bexxar, iodine I 131 tositumomab, Effective in Long Term Follow-up of Non-Hodgkin's Lymphoma
Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
research Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
Erlotinib may cause scarring hair loss.
research Trichoscopy and LC-OCT findings in sonidegib-induced alopecia in patients with advanced basal cell carcinoma
Sonidegib often causes hair loss, and LC-OCT helps identify early signs.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
research DEVELOPING NEW DUAL-ACTION ANTIVIRAL/ANTI-INFLAMMATORY SMALL MOLECULES FOR COVID-19 TREATMENT USING IN SILICO AND IN-VITRO APPROACHES
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
research Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
research Role of Inositol in Alopecia of Rats Fed Sulfasuxidine.
Inositol prevents hair loss and improves health in rats.
research Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.
EGFR inhibitors can cause skin issues, but managing them is important for treatment success.
research Abstract 5022: Keratin15 (Krt15) + are radio resistant and tumor-initiating cells in the mouse small intestine
Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.
research Abstract 5122: A novel topical candidate for chemotherapy and radiotherapy-induced alopecia (CRIA) through local modulation of apoptosis
A new topical treatment may prevent hair loss from cancer therapy by adjusting cell death processes in hair follicles.
research β-catenin-mediated hair growth induction effect of 3,4,5-tri-O-caffeoylquinic acid
3,4,5-tri-O-caffeoylquinic acid promotes hair growth by activating the β-catenin pathway.
research Image 1_Associations between ionomic profile and metabolic abnormalities in a murine model of sodium sulfide induced alopecia areata.tif
Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
research Synthesis and structure–activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands
The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
research Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
research Quercetin Nanocrystal Gel: A Novel Topical Therapeutic Strategy for Androgenetic Alopecia
Quercetin nanocrystal gel shows promise for hair regrowth in androgenetic alopecia.
research 022 Exploring the potential of the novel IFNγ aptamer TAGX-0003 as a treatment for alopeciaareata in pre-clinical models
The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
research Case Report: PTCH1 splice-site mutation and sonidegib treatment in Gorlin-Goltz syndrome: clinical insights from a family case study
Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.
research How to manage an 18-20 year old with hair loss that is not improved with ketoconazole?
Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.